Skip to main content
Quest Diagnostics

Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020

Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020

Authors: Bajema KL, Wiegand RE, Cuffe K, Patel SV, Iachan R, Lim T, Lee A, Moyse D, Havers FP, Harding L, Fry AM, Hall AJ, Martin K, Biel M, Deng Y, Meyer WA 3rd, Mathur M, Kyle T, Gundlapalli AV, Thornburg NJ, Petersen LR, Edens C.

JAMA Intern Med. 2020 Nov 24;e207976. doi: 10.1001/jamainternmed.2020.7976. Online ahead of print.

Specialties: COVID-19, Infectious Disease

Download key summary

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.